This announcement is a separate document:
アステラス製薬：抗体-薬物複合体PADCEV（エンホルツマブ ベドチン）進行性尿路上皮がん患者の一次治療を対象としたペムブロリズマブとの併用療法について欧州で承認を取得
Astellas Pharma: Antibody-drug complex PADCEV (enforzumab vedotin) obtained approval in Europe for combination therapy with pembrolizumab for primary treatment of patients with advanced urothelial cancer
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.